Field Application Scientist - EMEA

Manager, Technology Access Program

Regional Sales Director, East Coast

Regional Sales Director, West Coast

Field Application Engineer - EMEA

Software Engineer/Software Architect (C#)

1910 Genetics

20n Bio

3DBio Therapeutics

3T Biosciences

4D Molecular Therapeutics

64x Bio

76Bio

8Biomed

A-Alpha Bio

A2 Biotherapeutics

AavantiBio

Ab Studio

Abalone Bio

Abata Therapeutics

Abeona Therapeutics

Abintus Bio

Abiosciences

Absci

Accelevir Diagnostics

Accent Therapeutics

ACELYRIN

Acepodia

Achieve Life Sciences

Acrivon Therapeutics

Acutis Diagnostics

Adaptive Phage Therapeutics

Adcentrx Therapeutics

Adicet Bio

Aditum Bio

adMare BioInnovations

Admera Health

Adverum Biotechnologies

adyn

Aeglea BioTherapeutics

Aether Bio

Affini-T Therapeutics

Affinia Therapeutics

Affinivax

AgBiome

Agena Bioscience

AIRNA Bio

Akero Therapeutics

Akouos

Alamar Biosciences

Alector

AlivaMab Discovery Services

Alkahest

Alladapt Immunotherapeutics

Allakos

Allarta Life Science

Allay Therapeutics

AlloVir

Alloy Therapeutics

Alltrna

AlpaLifeBio

Alpha-9 Theranostics

Alphabioregen

Alpine Immune Sciences

Altis Biosystems

Alto Neuroscience

AltPep

Alumis

Alveo Technologies

Alveolus Bio

ALX Oncology

Alzheon

AmbAgon Therapeutics

Amberstone Biosciences

Amolyt Pharma

Amylyx Pharmaceuticals

AN2 Therapeutics

Anagram Therapeutics

Andes

Angiex

Angiocrine Bioscience

AnHeart Therapeutics

Annexon Biosciences

Anokion

Ansa Biotechnologies

Antheia

Anthos Therapeutics

AOA Dx

Apic Bio

Apollomics

Appia Bio

Applied Molecular Transport

Apriori Bio

Aptevo Therapeutics

Apton Biosystems

Aptose Biosciences

Aquinnah Pharmaceuticals

Aramis Biosciences

Arbor Biotechnologies

Arcadia Science

Arcellx

Arctoris

Arcturus Therapeutics

Arcutis Biotherapeutics

Arima Genomics

Ark Biotech

Alamar Biosciences is building a next-generation proteomic platform for plasma and liquid protein detection. Proteins present in blood samples have potential use as biomarkers for early detection and prevention of diseases, but many of these proteins are currently outside the detectable range due to their low abundance. Alamar is creating the most sensitive proteomic liquid biopsy platform that can profile thousands of proteins from microliters of blood. The fully automated platform achieves unparalleled sensitivity by using Alamar’s two breakthrough technologies: NULISA and Attobody. Together, Alamar’s platform can achieve single-digit attomolar detection, surpassing currently available technology and providing the potential to transform healthcare.

<p>Alamar Biosciences is building a next-generation proteomic platform for plasma and liquid protein detection. Proteins present in blood samples have potential use as biomarkers for early detection and prevention of diseases, but many of these proteins are currently outside the detectable range due to their low abundance. Alamar is creating the most sensitive proteomic liquid biopsy platform that can profile thousands of proteins from microliters of blood. The fully automated platform achieves unparalleled sensitivity by using Alamar’s two breakthrough technologies: NULISA and Attobody. Together, Alamar’s platform can achieve single-digit attomolar detection, surpassing currently available technology and providing the potential to transform healthcare.</p>


Find a biotech startup job.